You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Bristol-myers Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Drugs and US Patents for Bristol-myers

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol-myers ABRAXANE paclitaxel POWDER;INTRAVENOUS 021660-001 Jan 7, 2005 AB RX Yes Yes 9,511,046*PED ⤷  Try a Trial Y ⤷  Try a Trial
Bristol-myers ABRAXANE paclitaxel POWDER;INTRAVENOUS 021660-001 Jan 7, 2005 AB RX Yes Yes 7,758,891*PED ⤷  Try a Trial Y ⤷  Try a Trial
Bristol-myers ABRAXANE paclitaxel POWDER;INTRAVENOUS 021660-001 Jan 7, 2005 AB RX Yes Yes 7,923,536*PED ⤷  Try a Trial ⤷  Try a Trial
Bristol-myers INREBIC fedratinib hydrochloride CAPSULE;ORAL 212327-001 Aug 16, 2019 RX Yes Yes 7,528,143 ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bristol-myers

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol-myers THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 7,141,018 ⤷  Try a Trial
Bristol-myers THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 6,561,977 ⤷  Try a Trial
Bristol-myers THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 7,959,566 ⤷  Try a Trial
Bristol-myers THALOMID thalidomide CAPSULE;ORAL 020785-002 Jan 17, 2003 8,589,188 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BRISTOL-MYERS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 200 mg ➤ Subscribe 2006-09-25
➤ Subscribe For Injection Suspension 100 mg/vial ➤ Subscribe 2015-12-11
➤ Subscribe Capsules 50 mg and 100 mg ➤ Subscribe 2006-12-18
➤ Subscribe Capsules 150 mg ➤ Subscribe 2014-02-03
➤ Subscribe Injection 10 mg/vial ➤ Subscribe 2013-11-05

Supplementary Protection Certificates for Bristol-myers Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1951684 14/2021 Austria ⤷  Try a Trial PRODUCT NAME: FEDRATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER EIN PHARMAZEUTISCH ANNEHMBARES HYDRAT DAVON, INSBESONDERE FEDRATINIB-DIHYDROCHLORID-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/20/1514 (MITTEILUNG) 20210209
2049522 9/2015 Austria ⤷  Try a Trial PRODUCT NAME: DECLATASVIR; REGISTRATION NO/DATE: EU/1/14/939 (MITTEILUNG) 20140826
0688211 08C0036 France ⤷  Try a Trial PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
0688211 C300358 Netherlands ⤷  Try a Trial PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.